SCHEMBL783111

SCHEMBL783111

CCOC(=O)c1cccc(Oc2ccc3c(c2)S(=O)(=O)NCCO3)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 1/20 0.43
MAPT P10636 5/20 0.43
NPC1 O15118 5/20 0.43
RAB9A P51151 5/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
TP53 P04637 1/20 0.41
F10 P00742 2/20 0.41
F2 P00734 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
MAPK1 P28482 3/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
POLB P06746 1/20 0.39
GRIA2 P42262 1/20 0.39
USP2 O75604 1/20 0.39
TSHR P16473 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CTNNB1 P35222 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL783110 0.91 MAPT (0.42) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL760979 0.86 KEAP1 (0.48) KEAP1NPC1RAB9AKDM4EPOLB
SCHEMBL1973863 0.81 MEN1 (0.44) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL757862 0.81 KEAP1 (0.40) KEAP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL757860 0.81 KEAP1 (0.40) KEAP1MAPTNPC1RAB9ASMN1; SMN2
SCHEMBL756185 0.80 KEAP1 (0.44) KEAP1MAPTNPC1RAB9AKMT2A
SCHEMBL753235 0.80 KEAP1 (0.60) KEAP1GRIA2
SCHEMBL759673 0.79 MAPT (0.43) MAPTNPC1RAB9AMEN1KMT2A
SCHEMBL762296 0.78 GRIA2 (0.55) KEAP1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL757752 0.76 KEAP1 (0.42) KEAP1MAPTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569285-B2 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2013-10-29 US disclosed
US-20120071462-A1 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them LES LABORATOIRES SERVIER (FR) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071462-A1 Dihydrobenzoxathiazepine compounds, a process for their preparation and pharmaceutical compositions containing them GABRA1, GRM1, GABRA5 KEAP1 2482/4885MAPT 2781/4885NPC1 3425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.